TOP HEADLINES

Featured Story

FDA approves Dexcom smartphone-enabled device for continuous glucose monitor

Dexcom won FDA approval for its next-generation mobile communications device for diabetes monitoring, chalking up another regulatory win and furthering the company's R&D push.

Abbott seals a deal with Zeiss to sell cataract surgery products

Abbott made separate announcements related to devices focused on the eyes. The first was for a deal it reached with Carl Zeiss Meditec to sell the Swiss lensmaker's cataract surgery products alongside its own ocular surgery devices.

Tear-duct implant for eye drug delivery shows promise in clinical trial

Punctum plugs improve patient compliance and deliver drugs to the eye effectively, said the American Academy of Ophthalmology, citing the results of a Phase II study of Ocular Therapeutix's dexamethasone delivering plug, whose length is a fraction of the diameter of a dime.

Nanodevices could be unleashed by DNA-brick self-assembly

Strands of DNA interlocked like Lego bricks could become the key ingredient for tomorrow's nanoscale devices, Harvard University's Wyss Institute for Biologically Inspired Engineering says.

Veran raised $12M to commercialize lung biopsy device

St. Louis, MO-based Veran Medical closed a $12 million financing round. The company, specializing in thoracic navigation an biopsy for early detection of lung cancer, will use the funds toward continued commercial expansion in the U.S. and international launch of the Veran Thoracic Navigation System.

MORE NEWS

From Our Sister Sites

FierceBiotech

Earlier this year, Cytokinetics tanked as its lead prospect, a treatment for amyotrophic lateral sclerosis (ALS), missed its primary endpoint and a slew of secondary goals in a mid-stage trial. But the drug did come through on one measure of lung function, and, upon analysis of the results, the biotech believes that could be its ticket to FDA approval.

FierceBiotech

A panel of FDA advisers voted unanimously in favor of approving Novartis' new anti-inflammatory treatment, an expected positive outcome for the company as it races to be first in line among what promises to be a crowded field.